Back to results
US 11,890,290 B2Granted
Topical treatment of wounds with statins and cholesterol for scar reduction
AssigneeNorthwestern University
InventorsThomas A. Mustoe, Robert D. Galiano, Seok Jong Hong, Ping Xie, Shengxian Jia
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation.
Claims19
A method of preventing or reducing scar formation in the skin of a subject during wound healing comprising administering a composition to a wound site of the subject, wherein the composition comprises:
- i) 6-10% of a statin selected from the group consisting of simvastatin, rosuvastatin, lovastatin, cerivastatin, fluvastatin, mevastatin, pitavastatin, and pravastatin;
- ii) 1-15% of:
- a) cholesterol,
- b) cholesterol derivative selected from the group consisting of cholesteryl capronate, cholesteryl pelargonate, cholesteryl caprinate, cholesteryl undecilate, cholesteryl laurate, cholesteryl tridecilate, cholesteryl miristinate, cholesteryl palmitate, and cholesteryl stearate, or
- c) cholesterol analog selected from the group consisting of sitosterol, stigmasterol, fucosterol, spinasterol, campesterol, brassicasterol and ergosterol;
- and
- iii) a pharmaceutically acceptable carrier.
4 more elements
A composition comprising:
- i) 6-10% of a statin selected f rom the group consisting of simvastatin, rosuvastatin, lovastatin, cerivastatin, fluvastatin, mevastatin, pitavastatin, and pravastatin;
- ii) 1-15% of:
- a) cholesterol,
- b) cholesterol derivative selected from the group consisting of cholesteryl capronate, cholesteryl pelargonate, cholesteryl caprinate, cholesteryl undecilate, cholesteryl laurate, cholesteryl tridecilate, cholesteryl miristinate, cholesteryl palmitate, and cholesteryl stearate, or
- c) cholesterol analog selected from the group consisting of sitosterol, stigmasterol, fucosterol, spinasterol, campesterol, brassicasterol and ergosterol;
- and
- iii) a pharmaceutically acceptable carrier.
4 more elements
Dependencies are inferred from the claim text.